These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12150473)

  • 1. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
    Coker R
    Int J Tuberc Lung Dis; 2002 Aug; 6(8):649-50. PubMed ID: 12150473
    [No Abstract]   [Full Text] [Related]  

  • 2. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
    Gupta R; Raviglione MC; Espinal MA
    Int J Tuberc Lung Dis; 2001 Dec; 5(12):1078-9. PubMed ID: 11769764
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool.
    Migliori GB; Sotgiu G; Jaramillo E; Mirzayev F; Centis R; Colvin C; Richardson MD
    Int J Tuberc Lung Dis; 2009 Oct; 13(10):1305-8. PubMed ID: 19793438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational 'DOTS plus' for the control of MDR-TB.
    Espinal MA; Dye C; Raviglione M; Kochi A
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):561-3. PubMed ID: 10423218
    [No Abstract]   [Full Text] [Related]  

  • 6. Picking up the pace--scale-up of MDR tuberculosis treatment programs.
    Keshavjee S; Farmer PE
    N Engl J Med; 2010 Nov; 363(19):1781-4. PubMed ID: 21047219
    [No Abstract]   [Full Text] [Related]  

  • 7. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant tuberculosis in Ethiopia: problem scenarios and recommendation.
    Abate G
    Ethiop Med J; 2002 Jan; 40(1):79-86. PubMed ID: 12240570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB.
    Chan ED; Strand MJ; Iseman MD
    Clin Infect Dis; 2009 Mar; 48(5):e50-2. PubMed ID: 19191632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebuttal: Evidence and uncertainties.
    Gupta R; Espinal MA; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Aug; 6(8):651-3. PubMed ID: 12150474
    [No Abstract]   [Full Text] [Related]  

  • 12. Rebuttal, evidence and debate.
    Harper I
    Int J Tuberc Lung Dis; 2003 Jan; 7(1):100. PubMed ID: 12701844
    [No Abstract]   [Full Text] [Related]  

  • 13. High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia.
    Jugheli L; Rigouts L; Shamputa IC; Bram de Rijk W; Portaels F
    Int J Tuberc Lung Dis; 2008 May; 12(5):561-6. PubMed ID: 18419893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of multidrug-resistant tuberculosis: Update 2007.
    Yew WW; Leung CC
    Respirology; 2008 Jan; 13(1):21-46. PubMed ID: 18197909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estonia races to halt multidrug-resistant TB before HIV takes hold.
    Lindsay M
    Bull World Health Organ; 2002; 80(6):519. PubMed ID: 12132016
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effective control of drug-resistant TB: listening to other voices.
    Portero JL; Rubio M
    PLoS Med; 2006 Dec; 3(12):e542. PubMed ID: 17194207
    [No Abstract]   [Full Text] [Related]  

  • 17. Time to put boots on the ground: making universal access to MDR-TB treatment a reality.
    Keshavjee S; Farmer PE
    Int J Tuberc Lung Dis; 2010 Oct; 14(10):1222-5. PubMed ID: 20843411
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
    Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
    Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
    Mirsaeidi SM; Tabarsi P; Khoshnood K; Pooramiri MV; Rowhani-Rahbar A; Mansoori SD; Masjedi H; Zahirifard S; Mohammadi F; Farnia P; Masjedi MR; Velayati AA
    Int J Infect Dis; 2005 Nov; 9(6):317-22. PubMed ID: 16183321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of multi-drug resistant tuberculosis: practitioner's view point.
    Prasad R
    Indian J Tuberc; 2007 Jan; 54(1):3-11. PubMed ID: 17455417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.